To investigate whether LSD1 could be a valid therapeutic target for AML, the expression levels of LSD1 in a variety of AML cell lines were compared with that of normal bone marrow mononuclear cells (BMMNCs) by real-time quantitative PCR (qRT-PCR) and Western blot. This evidence concerns the gene KDM1A and acute myeloid leukemia.